An observational study in Movement Disorders (Incl Parkinsonism), Parkinsonian Disorders and Attention Impaired, sponsored by Inonu University. Enrolling by invitation at 1 site in Turkey. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Inonu University · Observational
Our study was planned to analyze motor function, endurance and sleep attention information in Parkinson's patients with detailed and objective measurements.
Parkinson's Disease (PD) is a neurodegenerative disease that occurs with the loss of dopaminergic neurons in the basal ganglia (BG) and subsequently affects multiple brain regions. There are studies that evaluate executive functions rather than cognitive functions in Parkinson's patients. However, objective evaluations of the attention parameter are quite rare. Accordingly, our study was planned to examine the effects of motor function, depression and sleep on attention in Parkinson's patients with detailed and objective measurements. Parkinson's patients (n=27) and healthy controls (n=27) aged between 40-85 will be included in the study. Balance evaluation of the individuals participating in the study was carried out by functional reaching test, one-leg standing test and Berg balance scale; Endurance with a 30-second sit-and-stand test; reaction time; with mobile application; muscle strength by hand dynamometer; functional mobility with time up and go test; walking speed, with 10 m walk test; attention with the P300 device; depression, with the Beck depression scale; Sleep quality will be assessed with the Pittsburg sleep questionnaire. At the end of the study, the effects of motor functions, sleep and depression on attention will be examined and compared with healthy controls.
218 studies on the registry are indexed under Parkinsonian Disorders; 63 are open to participants now.
This study's planned enrollment of 54 is below the median of 150 across 74 observational studies indexed under Parkinsonian Disorders.
Browse Parkinsonian Disorders studies →Inonu University is the lead sponsor of 394 studies on the registry; 95 are open to participants now.
Compared within Parkinsonian Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Movement Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Parkinson Diseases and Healty Control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Parkinson's patients will be included and the evaluations specified in the method section will be applied.
The healthy group will be included and the evaluations specified in the method section will be applied.
TUG
functional mobility
Time frame: second, day 1, Values over 12 seconds indicate the risk of falling
10 m walking test
walking speed
Time frame: second, day 1, lower results indicate better values, higher results indicate worse results
30 sec sit-stand test
endurance
Time frame: again,day 1, higher results indicate better values, lower results indicate worse results
berg balance test
balance
Time frame: score, day 1, The score is between 0-56. A high total score indicates a good result
one leg stance test
balance
Time frame: second, day 1, higher results indicate better values, lower results indicate worse results
functional reach test
balance
Time frame: centimeter, day 1, higher results indicate better values, lower results indicate worse results
hand dinamometer
strenght
Time frame: kilogram, day 1, higher results indicate better values, lower results indicate worse results
mobil application
reaction time
Time frame: second, day 1, lower results indicate better values, higher results indicate worse results
Pittsburg Sleep Quality İndex
sleep
Time frame: score, day 1, The score is between 0-21. A high total score indicates a bad result.
Beck Depression
depression
Time frame: score,day 1, The total score is between 0-63. A high total score indicates that the result is bad.
P300
attention
Time frame: second, day 1, lower results indicate better values, higher results indicate worse results
Started Jan 2024 (actual). Primary completion is estimated for Mar 2024, 2 months after the start.
Of 37 observational studies under Parkinsonian Disorders, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.